A Randomized, Placebo-Controlled 12-Month Trial of Divalproex and Lithium in Treatment of Outpatients With Bipolar I Disorder

By C. Bowden, J. Calabrese, S. McElroy, L. Gyulai, A. Wassef, F. Petty, H. Pope, J. Chou, P. Keck, L. Rhodes and 3 more. 2000

653 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

What is a "mood stabilizer"? An evidence-based response. (2004, background): “2000 (102)f 372 Both or unclear Bipolar I Partial remission Depressive relapse 1 year RCT Bowden et al.”
Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care (2011, background): “Equally, antidepressants (AD) such as paroxetine (116), and mood stabilizers, such as lithium and valproate (117-119), have been associated with weight gain (Table 3).”
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder (2018, background): “As well, two meta-analysis have concluded that divalproex is effective in preventing relapse of mood episodes (370, 372), and a population based cohort study in the UK showed that there were no differences in efficacy between divalproex, quetiapine and olanzapine in the maintenance treatment of bipo”